Filing Details
- Accession Number:
- 0001062993-22-016556
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-07-20 16:05:45
- Reporting Period:
- 2022-07-18
- Accepted Time:
- 2022-07-20 16:05:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1621443 | Zynerba Pharmaceuticals Inc. | ZYNE | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1327442 | E James Fickenscher | C/O Zynerba Pharmaceuticals, Inc. 80 W. Lancaster Avenue, Suite 300 Devon PA 19333 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-07-18 | 20,800 | $0.00 | 178,518 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2022-07-19 | 6,013 | $1.10 | 172,505 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Footnotes
- On July 18, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 20,800 performance-based restricted stock awards granted in a prior year.
- This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
Billionaire Hedge Funds
